Copy number variations and expression of MPDZ are prognostic biomarkers for clear cell renal cell carcinoma
Metrics: PDF 819 views | HTML 1387 views | ?
Yong-Sheng Huang1,*, Wen-Bin Liu1,*, Fei Han1, Jun-Tang Yang1, Xiang-Lin Hao1, Hong-Qiang Chen1, Xiao Jiang1, Li Yin1, Lin Ao1, Zhi-Hong Cui1, Jia Cao1 and Jin-Yi Liu1
1Institute of Toxicology, College of Preventive Medicine, Third Military Medical University, Chongqing 400038, PR China
*These authors have contributed equally to this work
Jin-Yi Liu, email: email@example.com
Jia Cao, email: firstname.lastname@example.org
Keywords: MPDZ, CNV, ccRCC, prognosis
Received: December 15, 2016 Accepted: July 12, 2017 Published: August 12, 2017
The vital copy number variation (CNV) plays a crucial role in clear cell renal cell carcinoma (ccRCC). MPDZ inhibit cell polarity associate with osmotic pressure response and cancer-related biological processes. In order to clarify the role of the CNV of MPDZ in the progression of ccRCC, we analyzed the CNV and expression of MPDZ and prognosis in ccRCC patients from The Cancer Genome Atlas data portal. Notably, we found that the deletion of MPDZ was the common CNV, which was present in 28.65% of ccRCC patients. With the development of tumors, the percentage of MPDZ deletion increased significantly (19.38% in stage I; 20.00% in stage II; 40.94% in stage III; and 45.00% in stage IV). The deletion of MPDZ significantly increased ccRCC risk (P=0.0025). Low MPDZ expression associated with its deletion was significantly associated with adverse outcomes in ccRCC patients (P=0.0342). Furthermore, immunohistochemical analysis by tissue microarray showed that MPDZ was expressed at lower levels in tumor tissues compared with adjacent tissues (P<0.01). Kaplan–Meier survival curves showed that ccRCC patients with low MPDZ expression had significantly shorter survival than those with high MPDZ expression (P=0.002). These results indicated that low MPDZ expression associated with CNV is a potential biomarker for the prognosis of ccRCC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.